Summary:
- Pfizer's RSV vaccine recommendation now covers high-risk adults aged 50-59.
- Analysts forecast a significant upside for Pfizer's stock price.
- The average brokerage recommendation for Pfizer is currently "Hold."
CDC Expands Pfizer's RSV Vaccine Recommendations
Pfizer Inc. (PFE, Financial) has announced an important update regarding its respiratory syncytial virus (RSV) vaccine, Abrysvo. The Centers for Disease Control and Prevention's (CDC) vaccine panel has voted to extend the recommended age range, now including high-risk adults aged 50 to 59. This expansion is contingent upon further approval from health authorities, a move that underscores the potential growth in demand for Pfizer's vaccine solutions.
Wall Street Analysts' Price Predictions
According to the latest analysis from 19 Wall Street professionals, Pfizer Inc (PFE, Financial) carries an average target price of $29.97. The forecasts range from a high of $41.43 to a low of $23.00, suggesting a robust potential increase of 35.98% from the current trading price of $22.04. For more comprehensive insights, visit the Pfizer Inc (PFE) Forecast page.
Analysts' Recommendations
The consensus from 23 brokerage firms places Pfizer Inc's (PFE, Financial) average brokerage recommendation at 2.6, which translates to a "Hold" status. This rating employs a scale from 1 to 5, where 1 indicates a Strong Buy, and 5 signals a Sell. This recommendation reflects the balanced sentiment among analysts regarding Pfizer's current market positioning.
GuruFocus Value Estimates
According to GuruFocus, Pfizer Inc's estimated GF Value is projected to be $28.62 within a year. This estimation offers a potential upside of 29.85% from its current price of $22.04. The GF Value is meticulously calculated, taking into account historical trading multiples, previous business growth, and future performance projections. Explore more on the Pfizer Inc (PFE, Financial) Summary page for detailed information.
